Newsbenzinga
Summit Therapeutics Says Ivonescimab Combination Extends Progression-Free Survival in Lung Cancer Patients
· Published
Article summary
Summit Therapeutics reported positive Phase 3 trial results for ivonescimab, extending progression-free survival in lung cancer patients.
An excerpt from the original article.
Comments —
Loading comments…